Holen Sie sich die Stockscreener-App
0.8882
0.20%
-0.0018
Handel nachbörslich:
.88
-0.0082
-0.92%
Schlusskurs vom Vortag:
$0.89
Offen:
$0.915
24-Stunden-Volumen:
3.62M
Relative Volume:
1.28
Marktkapitalisierung:
$39.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.2221
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
-18.51%
1M Leistung:
-55.81%
6M Leistung:
-39.58%
1J Leistung:
-87.92%
1-Tages-Spanne:
$0.8194
$0.915
1-Wochen-Bereich:
$0.8194
$1.07
52-Wochen-Spanne:
$0.79
$8.32
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Vergleichen Sie OTLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.8882 | 38.65M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Is Outlook Therapeutics Inc. showing insider buyingPortfolio Risk Report & Consistent Profit Alerts - khodrobank.com
Price action breakdown for Outlook Therapeutics Inc.Earnings Growth Report & Expert-Curated Trade Recommendations - Newser
How to build a custom watchlist for Outlook Therapeutics Inc.2025 Market Sentiment & Weekly Stock Breakout Alerts - Newser
Outlook Therapeutics shares fall 1.61% intraday after requesting a meeting with the US FDA. - AInvest
Will Outlook Therapeutics Inc. continue its uptrendJuly 2025 Market Mood & Proven Capital Preservation Methods - Newser
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewswire
Outlook Therapeutics to Present at EURETINA Innovation Spotlight - AInvest
Will Outlook Therapeutics Inc. benefit from seasonalityOil Prices & Free Verified High Yield Trade Plans - khodrobank.com
Long term hold vs stop loss in Outlook Therapeutics Inc.Market Trend Report & AI Driven Price Forecasts - Newser
Using economic indicators to assess Outlook Therapeutics Inc. potential2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - Newser
Is Outlook Therapeutics Inc. showing signs of accumulationAnalyst Upgrade & AI Based Buy and Sell Signals - Newser
Quantitative breakdown of Outlook Therapeutics Inc. recent moveTrade Signal Summary & Short-Term High Return Strategies - Newser
Technical signs of recovery in Outlook Therapeutics Inc.July 2025 WrapUp & Daily Volume Surge Signals - Newser
Tools to assess Outlook Therapeutics Inc.’s risk profileVolume Spike & Community Trade Idea Sharing - Newser
How to track smart money flows in Outlook Therapeutics Inc.July 2025 Sector Moves & Consistent Profit Trade Alerts - Newser
Will Outlook Therapeutics Inc. bounce back from current supportAnalyst Downgrade & Risk Controlled Daily Plans - Newser
Evaluating Outlook Therapeutics Inc. with trendline analysisWeekly Loss Report & Daily Momentum Trading Reports - Newser
Strategies to average down on Outlook Therapeutics Inc.Trade Signal Summary & Consistent Return Strategy Ideas - Newser
Will Outlook Therapeutics Inc. benefit from macro trendsPortfolio Profit Report & Daily Chart Pattern Signal Reports - Newser
Is Outlook Therapeutics Inc. part of any ETF2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - khodrobank.com
Published on: 2025-09-02 23:49:13 - Newser
Is Outlook Therapeutics Inc. meeting your algorithmic filter criteria2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
US FDA Emphasizes Primary Endpoint Primacy In Vatiquinone, Lytenava CRLs - insights.citeline.com
Analyzing Outlook Therapeutics Inc. with risk reward ratio charts2025 Price Targets & Long Hold Capital Preservation Tips - Newser
Outlook Therapeutics provides regulatory update on FDA review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the treatment of wet AMD - Eyes On Eyecare
Outlook Therapeutics receives second FDA CRL over wet AMD BLA - Eyes On Eyecare
Outlook Therapeutics’ Path to FDA Clarity and Commercialization of ONS-5010: Strategic and Financial Implications for Biotech Investors - AInvest
Outlook Therapeutics requests Type A meeting with FDA - MarketScreener
Outlook Therapeutics shares rise 1.65% intraday after requesting a Type A meeting with the FDA to discuss ONS-5010. - AInvest
Tools to assess Vanda Pharmaceuticals Inc.’s risk profile2025 Market Outlook & Verified Swing Trading Watchlist - Newser
Outlook Therapeutics Requests Type A Meeting with FDA - The Manila Times
Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative
Outlook Therapeutics Submits Type A Meeting Request to FDA. - AInvest
FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010 - Stock Titan
Real time breakdown of Outlook Therapeutics Inc. stock performance2025 Technical Overview & Expert Verified Stock Movement Alerts - Newser
Outlook Therapeutics Inc. stock volume spike explained2025 Price Action Summary & Verified Momentum Stock Ideas - Newser
Is Outlook Therapeutics Inc. stock trending bullishPortfolio Performance Report & Consistent Profit Trade Alerts - khodrobank.com
Outlook Therapeutics Reports Q3 Revenue - AOL.com
Wesson Brands Inc. stock outlook for YEAR2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Applying Wyckoff theory to Outlook Therapeutics Inc. stockVolume Spike & Proven Capital Preservation Methods - Newser
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):